8-K: Solsence Reports Record Fourth Quarter and Full-Year 2024 Financial Results, Eyes NASDAQ Uplisting

Solsence, Inc. announces record fourth quarter and full-year 2024 financial results, with revenue increasing 58% and 40% respectively, and plans to pursue a NASDAQ uplisting in 2025.

Summary

• Solsence, Inc. reported record revenue for both the fourth quarter and full year 2024.
• Fourth quarter revenue increased 57.5% to $12.6 million, compared to $8.0 million for the same period in 2023.
• Full year 2024 revenue increased 40% to a record $52.3 million, compared to $37.3 million in 2023.
• Gross profit increased 460% in the fourth quarter to a record $2.8 million, compared to $0.5 million for the same period in 2023.
• Gross profit for the full year 2024 was $16.2 million, a 107% increase over the $7.8 million in 2023.
• The company reported a net loss of $0.6 million for the fourth quarter, compared to a net loss of $2.1 million for the same period in 2023.
• Net income for the full year 2024 was $4.2 million, compared to a net loss of $4.4 million in 2023.
• The company is planning to pursue an uplisting to the NASDAQ market in 2025, subject to eligibility.
• Solsence initiated expanded batch-making capabilities at its Bolingbrook facility, increasing capacity to support over $200 million in annual revenue from the consumer products line.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with record revenue, improved profitability, and plans for a NASDAQ uplisting. While there are some risks mentioned, the overall tone is optimistic and suggests strong growth potential.

Positives

• Record revenue achieved for both the fourth quarter and full year 2024.
• Significant increase in gross profit for both the fourth quarter and full year 2024.
• The company achieved net income for the full year 2024, a turnaround from the previous year's net loss.
• Solsence is planning to pursue an uplisting to the NASDAQ market in 2025.
• Expanded batch-making capabilities at the Bolingbrook facility are expected to support over $200 million in annual revenue.
• Gross margin in the fourth quarter was 22%, compared to 6% for the same period in 2023.
• Gross margin for the twelve months ended December 31, 2024, was 31%, compared to 21% for the same period in 2023.

Negatives

• The company reported a net loss of $0.6 million for the fourth quarter, although this is an improvement from the $2.1 million net loss in the same period in 2023.

Risks

• The company's dependence on a limited number of key customers could be a risk if a customer cancels a purchase order or supply agreement.
• Uncertain demand for, and acceptance of, the company's products could impact future performance.
• The company's manufacturing capacity and product mix flexibility could be challenged by customer demand.
• The company's limited marketing experience could hinder growth.
• Competitive products and technologies could impact the company's market share.
• The company's dependence on patents and protection of proprietary information poses a risk.
• Potential new government regulations could be costly to comply with.
• The ability of the company to maintain an appropriate electronic trading venue is a risk factor.

Future Outlook

The company plans to pursue an uplisting to the NASDAQ market in 2025 and continues to make meaningful investments in operations, R&D, and its team to scale for long-term growth.

Management Comments

• 'We are very pleased to report record revenue for both the fourth quarter and full year 2024,' said Jess Jankowski, President, Chief Executive Officer, and Chief Financial Officer of Solsence.
• 'Our strong fourth-quarter results were driven by a shift in customer mix and the timing of key product launches, which, unlike previous years, occurred in the fourth quarter rather than the first.'
• 'We are incredibly proud to report a 40% increase in annual revenue over the prior year,' said Kevin Cureton, Chief Operating Officer.
• 'As we carry this momentum into 2025, we continue to make meaningful investments in operations, R&D, and our team, positioning us to scale for long-term growth.'
• 'Given the success of our commercial strategy and the related growth, the Company has decided to pursue an uplisting to the NASDAQ market in 2025, subject to eligibility,' said Mr. Jankowski.
• 'As part of this effort and additional related requirements we are anticipating, we also are beginning the search for a dedicated Chief Financial Officer.'

Industry Context

Solsence's focus on scientifically-driven health care solutions across beauty and life science categories aligns with the growing consumer demand for innovative and effective skin health products. The company's rebranding and focus on inclusivity also reflect broader industry trends towards more diverse and personalized beauty solutions.

Comparison to Industry Standards

• Comparing Solsence's 40% revenue growth to industry peers is difficult without specific competitor data, but high-growth companies in the beauty and personal care sector often see revenue increases in the 10-30% range.
• The gross margin of 31% is competitive within the specialty chemicals and ingredients sector, where margins can vary widely depending on product mix and value-added services.
• Companies like Croda International Plc, which also focuses on specialty ingredients for personal care, often report gross margins in the 35-45% range, suggesting Solsence has room for improvement.
• The planned NASDAQ uplisting is a common goal for growing companies like Solsence, as it can increase visibility and access to capital, similar to moves made by other OTCQB-listed companies seeking greater market recognition.

Stakeholder Impact

• Shareholders will likely view the record revenue and improved profitability positively.
• Employees can benefit from the company's growth and investments in operations and R&D.
• Customers can expect continued innovation and high-quality skin health solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its improved financial performance.

Next Steps

• Solsence will host its fourth quarter conference call on March 27, 2025, to discuss its financial results and provide a business and financial update.
• The company will pursue an uplisting to the NASDAQ market in 2025, subject to eligibility.
• The company is beginning the search for a dedicated Chief Financial Officer.

Key Dates

Keywords

Solsence, revenue, financial results, NASDAQ uplisting, skin health, Kleair, gross profit, net income, beauty, life science